Drugs / AVTX-009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06603077 | Sep 2024 → Feb 2026 | hidradenitis suppurativa | Avalo Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-05 | Avalo Therapeutics, Inc. | Results Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa May 05, 2026 4:01pm EDT avalotx.com ↗
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced positive topline results from its Phase 2 LOTUS trial evaluating the efficacy and safety of abdakibart in adults with moderate to severe hidradenitis suppurativa (HS). |
| 2024-07-09 | Avalo Therapeutics, Inc. | Regulatory Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa July 09, 2024 7:00am EDT avalotx.com ↗
Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-05 | Avalo Therapeutics, Inc. | Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa May 05, 2026 4:01pm EDT avalotx.com ↗ |
| 2025-10-29 | Avalo Therapeutics, Inc. | Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa October 29, 2025 7:00am EDT avalotx.com ↗ |
| 2024-10-08 | Avalo Therapeutics, Inc. | Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa October 08, 2024 7:00am EDT avalotx.com ↗ |
| 2024-07-09 | Avalo Therapeutics, Inc. | Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa July 09, 2024 7:00am EDT avalotx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVTX-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06603077 ↗ |
| Route | Subcutaneous | “AVTX-009 will be administered as a subcutaneous injection every 4 weeks.” NCT06603077 ↗ |